Scarica l'app Stockscreener
74.56
1.26%
-0.95
Dopo l'orario di chiusura:
74.56
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALC Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$75.51
Aprire:
$74.38
Volume 24 ore:
1.28M
Relative Volume:
0.79
Capitalizzazione di mercato:
$36.34B
Reddito:
$10.40B
Utile/perdita netta:
$980.00M
Rapporto P/E:
37.75
EPS:
1.9749
Flusso di cassa netto:
$1.61B
1 W Prestazione:
+0.12%
1M Prestazione:
-11.95%
6M Prestazione:
-0.73%
1 anno Prestazione:
-19.47%
Intervallo 1D:
$74.23
$76.06
Intervallo di 1 settimana:
$73.21
$76.06
Portata 52W:
$71.55
$99.20
Alcon Inc Stock (ALC) Company Profile
Nome
Alcon Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare ALC vs ISRG, BDX, MDLN, RMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
74.56 | 36.34B | 10.40B | 980.00M | 1.61B | 1.9749 |
ISRG
Intuitive Surgical Inc
|
452.07 | 160.56B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
154.51 | 43.95B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
44.28 | 35.94B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
224.09 | 32.65B | 5.40B | 1.49B | 1.78B | 10.12 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-01-30 | Iniziato | William Blair | Mkt Perform |
| 2026-01-20 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2026-01-09 | Downgrade | Stifel | Buy → Hold |
| 2025-12-11 | Downgrade | BofA Securities | Buy → Underperform |
| 2025-08-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-05-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-05-14 | Reiterato | BTIG Research | Buy |
| 2025-03-28 | Reiterato | Needham | Buy |
| 2025-03-25 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-01-24 | Reiterato | Needham | Buy |
| 2025-01-10 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | Reiterato | Needham | Buy |
| 2024-11-12 | Reiterato | Needham | Buy |
| 2024-10-10 | Aggiornamento | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-04-10 | Iniziato | Goldman | Buy |
| 2024-03-14 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | Iniziato | Bernstein | Outperform |
| 2023-12-18 | Downgrade | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | Iniziato | Stifel | Buy |
| 2023-12-04 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | Aggiornamento | Societe Generale | Sell → Hold |
| 2022-12-22 | Iniziato | Mizuho | Buy |
| 2022-11-17 | Downgrade | Societe Generale | Hold → Sell |
| 2022-08-11 | Downgrade | Societe Generale | Buy → Hold |
| 2022-05-13 | Ripresa | Credit Suisse | Outperform |
| 2022-05-12 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | Iniziato | Needham | Buy |
| 2022-03-11 | Iniziato | BofA Securities | Buy |
| 2022-01-18 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Iniziato | Oppenheimer | Perform |
| 2021-07-14 | Iniziato | Deutsche Bank | Buy |
| 2021-05-06 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-03-22 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-11-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-07-06 | Downgrade | Citigroup | Neutral → Sell |
| 2020-07-06 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-08 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Aggiornamento | Argus | Hold → Buy |
| 2020-03-24 | Aggiornamento | Societe Generale | Sell → Hold |
| 2020-03-13 | Aggiornamento | UBS | Neutral → Buy |
| 2020-03-05 | Iniziato | Citigroup | Neutral |
| 2020-02-26 | Aggiornamento | Berenberg | Hold → Buy |
| 2020-01-08 | Iniziato | Argus | Hold |
| 2019-10-29 | Iniziato | Stephens | Equal-Weight |
| 2019-08-21 | Reiterato | BofA/Merrill | Neutral |
| 2019-06-24 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-06-14 | Iniziato | BTIG Research | Neutral |
| 2019-05-10 | Iniziato | Robert W. Baird | Outperform |
| 2019-05-02 | Iniziato | Credit Suisse | Outperform |
Mostra tutto
Alcon Inc Borsa (ALC) Ultime notizie
Sight Sciences wins $34M patent ruling against Alcon - MSN
How The LENSAR (LNSR) Story Is Shifting After The Failed Alcon Deal And Target Reset - Yahoo Finance
Alcon Sets April 30, 2026 AGM, Proposes New Director and CHF 0.28 Dividend - The Globe and Mail
AB SUSTAINABLE INTERNATIONAL THEMATIC FUND INC's Alcon Inc(XSWX:ALC) Holding History - GuruFocus
Alcon Inc stock: Steady eye care leader amid market pressures? - AD HOC NEWS
Alcon Inc. (ALC) Stock Price, News, Quote & History - Yahoo Finance
Systane eye drops: Are Alcon’s German bestsellers worth it in the US? - AD HOC NEWS
Nanoscope Therapeutics Names Former Alcon Exec as Its New COO - National Today
Alcon Inc. (ALC) stock price, news, quote and history - Yahoo Finance Singapore
Alcon Publishes Agenda for 2026 Annual General Meeting - Yahoo Finance
Nanoscope brings in Alcon veteran as COO ahead of launch phase - The Pharma Letter
Alcon Inc. announces Annual dividend, payable on May 07, 2026 - MarketScreener
Analysts Offer Insights on Healthcare Companies: Alcon (ALC) and HCA Healthcare (HCA) - The Globe and Mail
Systane Eye Drops: Alcon's Leading Dry Eye Relief Product Driving Steady Growth in North American Op - AD HOC NEWS
List of 19 Acquisitions by Alcon (Apr 2026) - Tracxn
Alcon Inc Stock Faces Patent Setback and Merger Termination: Key Implications for NYSE:ALC Investors - AD HOC NEWS
ALC Stock Price, Quote & Chart | ALCON INC (NYSE:ALC) - ChartMill
Volume Report: Is Alcon Inc benefiting from innovation trendsDay Trade & Verified High Yield Trade Plans - baoquankhu1.vn
Street Watch: Should I hold or sell Alcon Inc now2026 PreEarnings & Weekly Top Stock Performers List - baoquankhu1.vn
Sight Sciences wins $34M in Alcon patent case, ongoing royalty - Investing.com Australia
Alcon (ALC) Faces $34 Million Verdict in Patent Case - GuruFocus
Alcon Fails to Undo $34 Million Patent Loss, Must Pay Royalties - Bloomberg Law News
Sight Sciences Wins $34 Million Patent Infringement Case Against Alcon, Secures Ongoing Royalties Through 2028 - minichart.com.sg
Sight Sciences Wins Infringement Lawsuit Against Alcon - National Today
Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent - The Manila Times
Sight Sciences (NASDAQ: SGHT) awarded $34M plus 10% Hydrus royalties - Stock Titan
Alcon Inc Stock: A Leader in Eye Care with Strong Growth Potential for North American Investors - ad-hoc-news.de
Aug Drivers: Will Alcon Inc stock go up in YEARQuarterly Portfolio Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Lensar stock slumps after hours on ending merger deal with Alcon over FTC pushback - MSN
Alcon Inc Stock: Global Leader in Eye Care with Strong Growth Potential for North American Investors - AD HOC NEWS
Alcon announces $81 million expansion in Cabell County, 75 new jobs expected - WOWK 13 News
Alcon Inc Stock: Global Leader in Eye Care Innovation and Steady Growth Potential for Investors - AD HOC NEWS
Alcon Inc. Stock: A Leader in Eye Care Innovation Driving Steady Growth for North American Investors - AD HOC NEWS
Alcon expansion to create more West Virginia jobs - DC News Now
Alcon in Lesage to start making new vision product - WOWK 13 News
Systane Eye Drops: Alcon's Leading Solution for Dry Eye Relief in North America - AD HOC NEWS
Analyst Upgrade: Is Alcon Inc benefiting from innovation trendsPortfolio Update Report & Expert Verified Movement Alerts - baoquankhu1.vn
Alcon Inc stock faces uncertainty as Lensar merger collapses, pivots to organic growth strategy - AD HOC NEWS
LENSAR Inc stock plunges as Alcon terminates merger over FTC antitrust block - AD HOC NEWS
LENSAR Inc stock faces prolonged uncertainty as Alcon merger awaits FTC approval amid regulatory del - AD HOC NEWS
LENSAR Inc stock faces uncertainty as Alcon merger awaits final regulatory approval amid pending FTC - ad-hoc-news.de
World Council of Optometry and Alcon Introduce Dry Eye Management Map - VisionMonday.com
Alcon Inc stock faces uncertainty as Lensar merger collapses, prompting strategic pivot to core eye - AD HOC NEWS
BTIG Reiterates 'Buy' Rating for Alcon (ALC) with $92 Price Targ - GuruFocus
Eaton Vance Worldwide Health Sciences Fund's Alcon Inc(XSWX:ALC) Holding History - GuruFocus
US LASIK Treatment Market Set to Witness Rapid Growth Through - openPR.com
Alcon Inc Azioni (ALC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):